RELMADA THERAPEUTICS INC Share Price Today: Live Updates & Key Insights

RELMADA THERAPEUTICS INC share price today is $5.99, up -2.88%. The stock opened at $6.45 against the previous close of $6.25, with an intraday high of $6.59 and low of $5.85.

RELMADA THERAPEUTICS INC Share Price Chart

RELMADA THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
us-stock

RELMADA THERAPEUTICS INC Share Price Performance

$5.99 -0.0288(-2.88%) RLMD at 23 Mar 2026 03:02 PM Biotechnology
Lowest Today 5.85
Highest Today 6.59
Today’s Open 6.45
Prev. Close 6.25
52 Week High 7.51
52 Week Low 0.24
Day’s Range: Low 5.85 High 6.59
52-Week Range: Low 0.24 High 7.51
1 day return -
1 Week return -1.78
1 month return +50.37
3 month return +35.26
6 month return +262.87
1 year return +1886.88
3 year return +157.87
5 year return -83.08
10 year return -

RELMADA THERAPEUTICS INC Institutional Holdings

Squadron Capital Management LLC 9.14

Adage Capital Partners Gp LLC 5.82

Spruce Street Capital LP 5.57

Marshall Wace Asset Management Ltd 4.35

Orbimed Advisors, LLC 3.56

Driehaus Capital Management LLC 2.56

Ikarian Capital, LLC 2.51

Millennium Management LLC 2.28

BRAIDWELL LP 2.16

Biotech Growth Ord 2.07

Vanguard Group Inc 1.64

Opaleye Management Inc 1.28

Geode Capital Management, LLC 1.17

BOOTHBAY FUND MANAGEMENT, LLC 1.14

Vanguard Institutional Extnd Mkt Idx Tr 1.09

Acadian Asset Management LLC 0.79

Two Sigma Investments LLC 0.78

Balyasny Asset Management LLC 0.75

BlackRock Inc 0.69

Fidelity Extended Market Index 0.53

Susquehanna International Group, LLP 0.53

AdvisorShares Psychedelics ETF 0.46

AdvisorShares Investments, LLC 0.44

Jane Street Group LLC 0.37

IMC US Ultra Micro Cap 0.27

Blackrock Extended Mkt Fund CF 0.26

Extended Equity Market Fund K 0.23

Fidelity Total Market Index 0.20

Fidelity Series Total Market Index 0.16

Spartan Extended Market Index Pool F 0.14

Pleiades Small Cap Equity A 0.14

NT Ext Equity Mkt Idx Fd - L 0.12

NT Ext Equity Mkt Idx Fd - NL 0.10

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.08

Spartan Total Market Index Pool G 0.08

Schwab Total Stock Market Index 0.07

Fidelity Nasdaq Composite Index 0.06

Northern Trust Extended Eq Market Idx 0.05

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.05

Vanguard U.S. Eq Idx £ Acc 0.04

RELMADA THERAPEUTICS INC Market Status

Strong Buy: 0

Buy: 0

Hold: 3

Sell: 0

Strong Sell: 0

RELMADA THERAPEUTICS INC Fundamentals

Market Cap 330.73 M

PB Ratio 46.9494

PE Ratio 0.0

Enterprise Value 430.52 M

Total Assets 94.00 M

Volume 1570553

RELMADA THERAPEUTICS INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-111570953 -111.6M, FY22:-152838570 -152.8M, FY21:-125798868 -125.8M, FY20:-58070363 -58.1M, FY19:-17318060 -17.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-10091496 -10.1M, Q2/2025:-9866442 -9.9M, Q1/2025:-17559465 -17.6M, Q3/2024:-21725970 -21.7M, Q2/2024:-17768122 -17.8M

About RELMADA THERAPEUTICS INC & investment objective

Company Information Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Dr. Sergio Traversa M.B.A., Pharm.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

RELMADA THERAPEUTICS INC FAQs

What is the share price of RELMADA THERAPEUTICS INC today?

The current share price of RELMADA THERAPEUTICS INC is $5.99.

Can I buy RELMADA THERAPEUTICS INC shares in India?

Yes, Indian investors can buy RELMADA THERAPEUTICS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy RELMADA THERAPEUTICS INC shares in India?

You can easily invest in RELMADA THERAPEUTICS INC shares from India by:

Can I buy fractional shares of RELMADA THERAPEUTICS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of RELMADA THERAPEUTICS INC?

RELMADA THERAPEUTICS INC has a market cap of $330.73 M.

In which sector does RELMADA THERAPEUTICS INC belong?

RELMADA THERAPEUTICS INC operates in the Biotechnology sector.

What documents are required to invest in RELMADA THERAPEUTICS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of RELMADA THERAPEUTICS INC?

The PE ratio of RELMADA THERAPEUTICS INC is N/A and the PB ratio is 46.95.